| Revenue growth | 10% YoY overall; 17% in Biopharmaceuticals; 16% in Biosimilars. |
|---|---|
| Margins | EBITDA 21%; Biosimilars 25%; Generics improved to 7%. |
| Demand visibility | Strong for insulins and new biosimilar launches in North America. |
| Management confidence | High; integration phase complete; focusing on profitable growth over market share. |
Growth
Biosimilars revenue rose 16% YoY; Generics grew 21%. Net profit saw massive recovery due to lower interest costs.
Outlook
Expect momentum acceleration in H2 FY27; Syngene revenue degrowth in FY27; aim for margin expansion and debt reduction.
Risks
Syngene faces temporary decline from key client; net debt increased by INR 1,100 Cr due to inventory stocking.
Last quarter's promises, checked
Delivered
- Guided Biosimilars growth → delivered 16% YoY (= BEAT)
- Guided interest cost reduction → delivered 23% YoY reduction (= BEAT)
- Guided US Aflibercept launch in H2 → delivered launch on schedule (= BEAT)
Partly delivered
- Guided margin expansion → delivered 21% group margin vs 22% FY26 base (= PARTIAL)
Missed
- Guided debt reduction priority → delivered INR 1,100 Cr net debt increase (= MISS)
- Guided Syngene stable performance → delivered 16% revenue decline (= MISS)
Investor Presentation filed with BSE, NSE: BIOCON. Summary written with AI assistance from the document.
Biocon Ltd: key numbers
- Share price
- ₹360.00
- Market cap
- ₹58,669 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 118.5×Sector 47.4×
- Promoter holding
- 44.68%-0.23% QoQ
- FII holding
- 8.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Business Update
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Biocon Bags New Order from Bahiafarma and Bionovis
Biocon secured a 10-year supply contract for Pertuzumab in Brazil under a government program. The partnership involves milestone payments and revenue sharing for the company.
- From
- Bahiafarma and Bionovis (Brazil PDP program)
- Execution
- 10 years
Biocon Other Announcement
Biocon has initiated the remittance of the final dividend for FY 2025-26. This notification confirms the dispatch process for shareholders.
Biocon Capital Structure Change
Mylan Inc. filed a revised SAST disclosure clarifying the sale of 9.19 crore shares in Biocon Limited. The seller's post-disposal holding is now correctly reported as Nil.
Biocon Regulatory Approval
Biocon received marketing approval from Japan's MHLW for its Pegfilgrastim biosimilar. This approval enhances Biocon's biosimilar portfolio and market access in Japan.
Biocon Business Update
Biocon's US subsidiary received U.S. FDA approval for the Yesintek® prefilled autoinjector. This supplemental approval enhances the company's immunology portfolio.